223 related articles for article (PubMed ID: 11721171)
1. T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.
Tsirigotis P; Economopoulos T; Rontogianni D; Dervenoulas J; Papageorgiou E; Bollas G; Mantzios G; Kalantzis D; Koumarianou A; Raptis S
Oncology; 2001; 61(4):257-64. PubMed ID: 11721171
[TBL] [Abstract][Full Text] [Related]
2. T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma.
Aki H; Tuzuner N; Ongoren S; Baslar Z; Soysal T; Ferhanoglu B; Sahinler I; Aydin Y; Ulku B; Aktuglu G
Leuk Res; 2004 Mar; 28(3):229-36. PubMed ID: 14687617
[TBL] [Abstract][Full Text] [Related]
3. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
4. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
Kim YS; Ji JH; Ko YH; Kim SJ; Kim WS
Acta Haematol; 2014; 131(3):156-61. PubMed ID: 24192382
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
6. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
7. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
8. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma.
Kim DH; Baek JH; Chae YS; Kim YK; Kim HJ; Park YH; Song HS; Chung JS; Hyun MS; Sohn SK
Leukemia; 2007 Oct; 21(10):2227-30. PubMed ID: 17554383
[No Abstract] [Full Text] [Related]
9. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
11. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
[TBL] [Abstract][Full Text] [Related]
12. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
Rudzki Z; Rucińska M; Jurczak W; Skotnicki AB; Maramorosz-Kurianowicz M; Mruk A; Piróg K; Utych G; Bodzioch P; Srebro-Stariczyk M; Włodarska I; Stachura J
Pol J Pathol; 2005; 56(1):37-45. PubMed ID: 15921012
[TBL] [Abstract][Full Text] [Related]
13. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
[TBL] [Abstract][Full Text] [Related]
14. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience.
Kwak LW; Wilson M; Weiss LM; Doggett R; Dorfman RF; Warnke RA; Horning SJ
J Clin Oncol; 1991 Aug; 9(8):1426-31. PubMed ID: 1712837
[TBL] [Abstract][Full Text] [Related]
15. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis.
Bouabdallah R; Mounier N; Guettier C; Molina T; Ribrag V; Thieblemont C; Sonet A; Delmer A; Belhadj K; Gaulard P; Gisselbrecht C; Xerri L
J Clin Oncol; 2003 Apr; 21(7):1271-7. PubMed ID: 12663714
[TBL] [Abstract][Full Text] [Related]
16. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
17. [T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis].
Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Luo XL
Zhonghua Bing Li Xue Za Zhi; 2005 Dec; 34(12):771-5. PubMed ID: 16545182
[TBL] [Abstract][Full Text] [Related]
18. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
[TBL] [Abstract][Full Text] [Related]
19. [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
Schneider T; Molnár Z; Deák B; Várady E; Tóth E; Csomor J; Matolcsy A; Lovey J; Lengyel Z; Petri K; Gaudi I; Rosta A
Orv Hetil; 2009 Nov; 150(44):2019-26. PubMed ID: 19861288
[TBL] [Abstract][Full Text] [Related]
20. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.
Chihara D; Westin JR; Oki Y; Ahmed MA; Do B; Fayad LE; Hagemeister FB; Romaguera JE; Fanale MA; Lee HJ; Turturro F; Samaniego F; Neelapu SS; Rodriguez MA; Fowler NH; Wang M; Davis RE; Nastoupil LJ
Cancer; 2016 Oct; 122(20):3145-3151. PubMed ID: 27351173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
